Article
Raman-guided analysis of drug response combined with chemometrics helps monitor the effect of ruxolitinib on acute lymphoblastic leukemia.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy - 5 Jun 2026
Adamczyk Adriana, Jakubowska Justyna, Szewczyk Marta, Nowakowska Anna M, Stawoski Kacper, Pastorczak Agata, Młynarski Wojciech, Baranska Małgorzata, Ostrowska Kinga, Majzner Katarzyna
Abstract excerpt
Ruxolitinib (RUX), a selective JAK1/JAK2 inhibitor, is considered a therapeutic option for childhood B-cell precursor acute lymphoblastic leukemia (B-ALL) with JAK2 gain-of-function mutations. This study aimed to evaluate whether Raman spectroscopy combined with chemometric analysis can monitor the biochemical effects of RUX treatment in B-ALL cell lines. We employed single-cell confocal Raman imaging, flow...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
